Skip to content

Adenine Base Editor ABE7.10 Corrects Sickle Cell Disease HBB E6V Mutation in Patient-Derived Hematopoietic Stem Cells With >84% Editing Efficiency and Preserved Engraftment

2016 · Princeton Journal of Pre-Collegiate Research · 0 citations

TL;DR

These findings contribute empirically to hematology and genome editing and carry actionable implications for the design of programs and policies targeting SCD gene therapy clinical translation, base editing HSPC platform for hemoglobinopathies, and off-target safety framework for clinical-grade base editor development.

Abstract

This study investigates adenine base editor ABE7.10 correction of the sickle cell disease HBB E6V point mutation in patient-derived CD34+ hematopoietic stem and progenitor cells with assessment of editing efficiency, off-target profile, and xenograft engraftment within the context of hematology and genome editing, an area of growing scientific importance given its implications for SCD gene therapy clinical translation, base editing HSPC platform for hemoglobinopathies, and off-target safety framework for clinical-grade base editor development. Using mRNA electroporation of ABE7.10 into mobilized CD34+ HSPCs, deep amplicon sequencing for HBB A-to-G conversion at position 6, whole-genome sequencing for off-target SNVs (n=5 donors), and 16-week NSG xenograft with human chimerism and erythroid differentiation assessment, we examine ABE7.10 adenine base editor converting A•T to G•C at HBB codon 6 (glutamic acid E6V), reverting the sickle mutation (GAG→GTG) back to wild-type sequence without double-strand breaks, reducing genotoxicity risk vs. nuclease-based approaches while achieving therapeutically relevant editing in long-term repopulating HSCs in CD34+ HSPCs from 8 SCD donors; n=40 NSG xenograft mice (5 per donor) transplanted with edited or mock-treated cells; 16-week follow-up with bone marrow analysis drawn from Ridgemont Stem Cell Institute GMP-compatible electroporation facility with 4D-Nucleofector, Illumina MiSeq for amplicon sequencing, and NSG xenograft facility with 16-week engraftment assessment. Results indicate that mean A-to-G editing efficiency 84.2% at HBB codon 6 (range 78-91% across donors); bystander edits <2.4%; no enrichment of off-target SNVs above background in WGS; human chimerism 48.4% at 16 weeks; HbS/HbA ratio reduced from 100% to 18.4% in erythroid progeny (p < 0.001), with 84.2% editing efficiency; HbS reduced to 18.4%; 48.4% engraftment; no enriched off-targets as the primary quantitative benchmark. Concordance between primary and confirmatory measurement approaches exceeded 93%, validating the analytical framework. These findings contribute empirically to hematology and genome editing and carry actionable implications for the design of programs and policies targeting SCD gene therapy clinical translation, base editing HSPC platform for hemoglobinopathies, and off-target safety framework for clinical-grade base editor development.

View source

Similar papers

Open access Sep 2026

Prime Editing Corrects the HBB Codon 8/9 (+G) Mutation in Patient-Derived Induced Pluripotent Stem Cells and Restores β-Globin Expression in iPSC-Derived Erythroid Cells

Background Homozygosity for the HBB codon 8/9 (+G) frameshift (c.27dup (p.Ser10ValfsTer14)) causes transfusion-dependent β⁰-thalassaemia and is common in South Asia. Prime editing can reverse this insertion without double-strand breaks or donor DNA, but its efficiency depends on pegRNA design. Methods We derived Sendai...

Irfan Hussain, Kainaat Mumtaz, Maliha Javed et al. · 0 citations
#gene editing Open access Sep 2026

Development of CRISPR_SCD001, an Autologous Hematopoietic Stem Cell Gene Therapy for Sickle Cell Disease after CRISPR-Cas9 Mediated Correction.

Data support initiation of a first-in-human phase I trial of CRISPR_SCD001 for sickle patients presenting with severe pathology, and generates a clinical-grade, cryopreserved CD34+ cell product that corrects the sickle mutation, restores anti-sickling hemoglobins, and meets pre-clinical safety criteria.

M. DeWitt, Beatriz Campo-Fernández, Sohini Roy et al. · 0 citations
#gene editing Sep 2026

Prime editing of human hematopoietic stem cells for correction of GATA2 deficiency.

PASSIGE (prime editing-assisted site-specific integrase gene editing) is reported in CD34+ HSPCs, developing a more broadly applicable, double-strand break-independent complementary DNA insertion strategy with the potential to address a large proportion of alleles causing GATA2 deficiency.

J. H. Wolff, T. W. Skov, S. R. Dorset et al. · 0 citations
Open access Oct 2026

Characterisation of the patient-specific induced pluripotent stem cell line UKEi075-A carrying the heterozygous PRKAG2 frameshift variant c.769_770del (p.E257Kfs*15).

Missense variants in PRKAG2, the gene encoding for the γ2-subunit of adenosine monophosphate-activated protein kinase (AMPK), can cause hypertrophic cardiomyopathy, cardiac conduction defects and glycogen storage disorders. Clinical consequences evoked by truncating PRKAG2 variants are poorly understood. Dermal fibrobl...

Benedict Hoffmann, Tim Knochenhauer, J. Schlobohm et al. · 0 citations
Review Open access 2026

Prime Editing in Selected Disease Applications: Cancer Models, Primary Immunodeficiency, β-Hemoglobinopathies, HIV/CCR5, and Neurodegenerative Targets

Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 transformed genome engineering by enabling targeted DNA cleavage, but double-strand breaks can generate heterogeneous repair products and larger genomic alterations. Prime editing is a search-and-replace genome-editing strategy that combines a Cas9...

Shaan D. Shah, Thomas Zhang · 0 citations
#gene editing Open access Sep 2026

In vivo HSPC gene therapy of hemoglobinopathies without drug selection of corrected cells

In vitro studies in an erythroid progenitor cell line and primary CD34+ cells demonstrated that the EPORW439* variant conferred a strong proliferative advantage to therapeutically modified erythroid progenitors, establishing a strategy to amplify the therapeutic benefit of otherwise limited in vivo HSPC gene editing fo...

Akshara Sakunthala Velmurugan, K. Paschoudi, Jack A. Queenan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.